ReviewCancers2021
Pathogenetic Features and Current Management of Glioblastoma.
Review in Cancers, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed, 1 synthesis or guideline pooled it, 60 citations in OpenAlex.
- Efficacy and safety of 5-aminolevulinic acid-guided surgery versus white-light resection in newly diagnosed glioblastoma: a systematic review and meta-analysis.Neurosurgical review · 2026Pooled it
- Review
- ELF3 drives glioblastoma multiforme progression through the regulation of MXRA8 expression.Scientific reports · 2026Article
- From Classical to Emerging Biomarkers of Brain and Central Nervous System Tumors. An Evidence-Based Review with a Focus on Gliomas.Cellular and molecular neurobiology · 2026Review
- A characterisation of the immune cells in immunocompetent and immunodeficient mice with orthotopic brain tumors.Clinical & translational immunology · 2026Article
- MicroRNAs and immunotherapy in testicular germ cell tumors: opportunities and challenges for modulation of the immune microenvironment.Frontiers in immunology · 2026Review
- High-Throughput 3D Glioblastoma Model in Glycosaminoglycan Hydrogels for Personalized Therapeutic Screening.Macromolecular bioscience · 2026Article
- Promoting the therapeutic potential of interleukin-7 (IL-7) by expression in viral vectors.Cancer gene therapy · 2025Review
- The Effect of Bee Venom and Melittin on Glioblastoma Cells in Zebrafish Model.Molecules (Basel, Switzerland) · 2025Article
- Therapeutic Potential of Sea Cucumber-Derived Bioactives in the Prevention and Management of Brain-Related Disorders: A Comprehensive Review.Marine drugs · 2025Review
- Understanding the interplay between oHSV and the host immune system: Implications for therapeutic oncolytic virus development.Molecular therapy : the journal of the American Society of Gene Therapy · 2025Review
- Targeting EGFR and PI3K/mTOR pathways in glioblastoma: innovative therapeutic approaches.Medical oncology (Northwood, London, England) · 2025Review
- Design, Synthesis, and Computational Evaluation of 3,4-Dihydroquinolin-2(Pharmaceuticals (Basel, Switzerland) · 2025Article
- Prospects of marine-derived compounds as potential therapeutic agents for glioma.Pharmaceutical biology · 2024Review
- Review
- Impact ofBiomolecules & biomedicine · 2024Article
- Effect ofMolecules (Basel, Switzerland) · 2024Article
- A novel oncolytic HSV co-expressing IL-12 and anti-PD-1 for glioblastoma.Molecular therapy. Oncology · 2024Article
- Oncolytic herpes simplex virus expressing IL-2 controls glioblastoma growth and improves survival.Journal for immunotherapy of cancer · 2024Article
- Folic Acid Functionalized AQ4N/Gd@PDA Nanoplatform with Real-Time Monitoring of Hypoxia Relief and Enhanced Synergistic Chemo/Photothermal Therapy in Glioma.International journal of nanomedicine · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Glioblastoma (GBM) is the most common form of primary malignant brain tumor with a devastatingly poor prognosis. The disease does not discriminate, affecting adults and children of both sexes, and has an average overall survival of 12-15 months, despite advances in diagnosis and rigorous treatment with chemotherapy, radiation therapy, and surgical resection. In addition, most survivors will eventually experience tumor recurrence that only imparts survival of a few months. GBM is highly heterogenous, invasive, vascularized, and almost always inaccessible for treatment. Based on all these outstanding obstacles, there have been tremendous efforts to develop alternative treatment options that allow for more efficient targeting of the tumor including small molecule drugs and immunotherapies. A number of other strategies in development include therapies based on nanoparticles, light, extracellular vesicles, and micro-RNA, and vessel co-option. Advances in these potential approaches shed a promising outlook on the future of GBM treatment. In this review, we briefly discuss the current understanding of adult GBM's pathogenetic features that promote treatment resistance. We also outline novel and promising targeted agents currently under development for GBM patients during the last few years with their current clinical status.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.